<DOC>
	<DOCNO>NCT00002048</DOCNO>
	<brief_summary>To evaluate safety tolerance chronic administration Retrovir ( AZT ) HIV-infected adult patient without clinical manifestation disease . To assess efficacy AZT therapy treatment HIV disease patient .</brief_summary>
	<brief_title>The Efficacy Safety Retrovir Patients Infected With HIV Who Are Asymptomatic ( CDC Group II ) Have Persistent Generalized Lymphadenopathy ( CDC Group III )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphatic Diseases</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow exclude : Prior history malignancy cutaneous basal cell cervical carcinoma . Other significant , chronic underlie medical illness would impair study completion . Liver dysfunction demonstrate lab result . Laboratory evidence compromise bone marrow function . Concurrent Medication : Excluded : Any experimental agent . Any probenecidcontaining product . Patients exclude history symptom characteristic CDC class I IV include following : Unintentional weight loss great 10 lb , 10 percent usual body weight within last 16 week . Unexplained fever &gt; 38.5 degree C 14 consecutive day 15 day previous 30day period . Unexplained diarrhea define = &gt; 2 liquid stool per day persist = &gt; 14 day 15 day 30day period . OR History secondary infection associate AIDS relate complex ( ARC ) include : Recurrent oral candidiasis document morphology response antifungal therapy within 3 year . Herpes zoster infection within 3 year . Oral hairy leukoplakia time . OR History opportunistic disease fulfil CDC surveillance definition AIDS . Signs symptom baseline characteristic acute HIV disease ( CDC group I ) . Evidence significant neurologic dysfunction currently define CDC follow standard neurologic screening AIDS Dementia Assessment . Prior Medication : Excluded : Previous treatment great 3 month duration antiretroviral compound zidovudine ( AZT ) . Excluded within 4 week study entry : Treatment potentially myelosuppressive drug , nephrotoxic agent , experimental therapy . Excluded within 3 month study entry : Antiretroviral drug biologic response modifier . Excluded within 4 month study entry : Systemic corticosteroid . Patients must meet following criterion : HIV infection demonstrate ELISA confirm Western blot . Signs symptoms HIV disease limit characteristic CDC group II ( asymptomatic ) III ( persistent generalize lymphadenopathy PGL ) . Ability give inform consent . Willingness follow originate medical center entire 3year duration study . Active drug alcohol abuse sufficient investigator 's opinion prevent compliance study regimen .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1989</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>